Revolution Medicines, Inc.
RVMD· Nasdaq
Released Aug 10, 2020, before the open
10-Q filed Aug 10, 2020, 41 days after period end · 0001564590-20-038663
| Metric | Q2 2020 | Q2 2019 |
|---|---|---|
| Revenue | $10.03M | $12.28M |
| Net Income | -$27.22M | -$10.12M |
| EPS Diluted | -$0.46 | -$4.85 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Jun 30, 2020 · filed Aug 10, 2020 · 41 d after period end
+8.7% from the close of Aug 7, 2020 to the close of Aug 10, 2020, the first after the release.